Literature DB >> 31377285

Neovascularization in Fellow Eye of Unilateral Neovascular Age-related Macular Degeneration According to Different Drusen Types.

Junwon Lee1, Seonghee Choi1, Christopher Seungkyu Lee2, Min Kim2, Sung Soo Kim1, Hyoung Jun Koh1, Sung Chul Lee1, Suk Ho Byeon3.   

Abstract

PURPOSE: To investigate the incidence of fellow eye (FE) neovascular age-related macular degeneration (nAMD) in patients with unilateral nAMD according to FE drusen type.
DESIGN: Retrospective cohort study.
METHODS: Between January 2013 and June 2016, 434 consecutive patients with naïve nAMD were enrolled. We selected 280 eligible patients with treatment-naïve, unilateral nAMD for analysis (280/280 = 100% patients were followed up at 2 years; 50/280 = 17.9% patients were followed up at 5 years). The incidence and hazard ratios (HR) of FE nAMD according to age, sex, choroidal thickness, nAMD subtype, and drusen type were analyzed.
RESULTS: The 5-year incidence of FE nAMD was 20.9%. The incidences of the soft plus subretinal drusenoid deposits (SDD), soft drusen only, and SDD only groups were 76.4%, 46.2%, and 25.7%, respectively; they were significantly higher than the no drusen group (vs 3.6%; P < .001, P < .001, P < .001). There was no significant difference between the pachydrusen and no drusen groups (7.1% vs 3.6%; P = .101). The multivariate Cox regression hazard model revealed older age (HR, 1.053; P = .031) and drusen type were significant (P = .001). Compared with the no drusen group, the soft drusen plus SDD, soft drusen only, and SDD groups showed an HR of 18.460 (P = .001), 8.302 (P = .015), and 5.465 (P = .082), respectively. Pachydrusen was not shown to be a significant risk factor compared to the no drusen group (HR, 2.417; P = .281).
CONCLUSION: The incidence of FE nAMD was significantly different with respect to drusen type. Soft drusen plus SDD had the highest risk of neovascular AMD, followed by soft drusen only and SDD only.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31377285     DOI: 10.1016/j.ajo.2019.07.013

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Predicting conversion to wet age-related macular degeneration using deep learning.

Authors:  Jason Yim; Reena Chopra; Terry Spitz; Jim Winkens; Annette Obika; Christopher Kelly; Harry Askham; Marko Lukic; Josef Huemer; Katrin Fasler; Gabriella Moraes; Clemens Meyer; Marc Wilson; Jonathan Dixon; Cian Hughes; Geraint Rees; Peng T Khaw; Alan Karthikesalingam; Dominic King; Demis Hassabis; Mustafa Suleyman; Trevor Back; Joseph R Ledsam; Pearse A Keane; Jeffrey De Fauw
Journal:  Nat Med       Date:  2020-05-18       Impact factor: 53.440

2.  Clustering of eyes with age-related macular degeneration or pachychoroid spectrum diseases based on choroidal thickness profile.

Authors:  Young Ho Kim; Boram Lee; Edward Kang; Jaeryung Oh
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

3.  Clinical Characteristics of Neovascular Age-Related Macular Degeneration without Typical Drusen.

Authors:  Hiroyuki Kamao; Katsutoshi Goto; Kento Matsuno; Kenichi Mizukawa; Atsushi Miki; Junichi Kiryu
Journal:  J Ophthalmol       Date:  2021-04-27       Impact factor: 1.909

4.  Macular neovascularization in eyes with pachydrusen.

Authors:  Kelvin Yi Chong Teo; Kai Xiong Cheong; Ricardo Ong; Haslina Hamzah; Yasuo Yanagi; Tien Yin Wong; Usha Chakravarthy; Chui Ming Gemmy Cheung
Journal:  Sci Rep       Date:  2021-04-05       Impact factor: 4.379

5.  Pigmentary abnormality without significant drusen as a risk factor for late age-related macular degeneration.

Authors:  Junwon Lee; Hyun Goo Kang; Hae Rang Kim; Christopher Seungkyu Lee; Min Kim; Sung Soo Kim; Suk Ho Byeon
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.379

6.  Age-related macular degeneration eyes presenting with cuticular drusen and reticular pseudodrusen.

Authors:  Je Moon Yoon; Dong Hoon Shin; Mingui Kong; Don-Il Ham
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.